Phase 3 results reported in NEJM
In a phase 3 trial, inotuzumab ozogamicin demonstrated a significantly higher rate of response and minimal residual disease negativity compared to standard-of-care chemotherapy for patients with refractory or relapsed acute lymphoblastic leukemia (ALL), reports Cleveland Clinic’s Anjali S. Advani, MD, Director, Inpatient Leukemia Program.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“The prognosis for patients with ALL is poor and therapy has not changed significantly during the past decade. New therapies are needed. We hope this study will lead to FDA approval of this drug, adding a new weapon to our arsenal that improves outcomes for patients,” Dr. Advani states.
Trial results were published in the June 12 New England Journal of Medicine in an article co-authored by Dr. Advani and an international team of researchers. Also see Dr. Advani’s previous Consult QD article, Evaluating Novel Therapies in Acute Leukemia: Promising Clinical Trials Underway.
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Cleveland Clinic oncologists’ selected abstracts
On-demand stem cell mobilizer is an effective salvage strategy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria